EPI-743 Phase 2B Friedreich Ataxia clinical trial to be initiated. Friedreich’s Ataxia Research Alliance (FARA) Press release. Downingtown, PA, November 15, 2012.
“We are tremendously excited about the encouraging results Edison Pharma’s team has obtained with EPI-743 in mitochondrial disease, and about the promising prospects for this upcoming multicenter Friedreich’s ataxia phase 2B study. We strongly encourage all Friedreich’s ataxia patients interested in participating to take the steps above to prepare for this important trial,” said FARA President Ron Bartek.
Thursday, November 15, 2012
Adaptive Clinical Trials in Orphan Drug Development
Adaptive Clinical Trials in Orphan Drug Development. Authored by James Sheppard. Liftstream Life Science Newsletter
The benefit to companies and patients in the rare disease space is clear. Adaptive trials offer the possibility to help reduce not only the financial burden but the time constraints too.
The benefit to companies and patients in the rare disease space is clear. Adaptive trials offer the possibility to help reduce not only the financial burden but the time constraints too.
Subscribe to:
Posts (Atom)
